Search Results

Clinical Trials (8304)
Therapy Area (2570)
Technology (2449)
Suvoda WP (2264)
Approvals (1615)
Covid-19 (1596)
Infectious Disease (1285)
Genomics (1205)
API Manufacturers (1131)
Oncology (992)
Drug Development (926)
Clinical Trials Arena (764)
COVID Cross-sector Impact Brief (530)
Country Risk Report Q4 2021 - Professional Services (506)
Oracle NAS WP (464)
SiteNavigation (455)
Operations (296)
Central Nervous System (272)
Supply Chain (192)
Neurology (191)

News Analysis and Comments (13358)
White Papers (754)
Projects (699)
Press Releases (610)
Suppliers (488)
Supplier Products (95)

Clinical Trials (55)
Contract Research Organization (51)
Consulting (13)
Clinical Data Management Services (12)
Cloud (12)
AI (11)
Clinical Pharmacological Services (11)
Cybersecurity (11)
IoT (11)
Analytical Services (10)
Bioavailability Studies (10)
Biomarker Services (10)
Clinical Trial Site Selection and Management (10)
Contract Manufacturers (10)
Biostatistics Services (9)
Clinical Development Services (9)
Clinical Trial Design Services (9)
Clinical Trial Patient Recruitment (9)
ESG (9)
Pharmacovigilance (9)

United States (3812)
Global (850)
North America (675)
United Kingdom (594)
Europe (465)
China (260)
Asia-Pacific (185)
Switzerland (150)
Australia (137)
France (124)
Japan (117)
Canada (114)
Germany (87)
India (86)
Israel (68)
South Korea (48)
Brazil (45)
Middle East & Africa (39)
Denmark (38)
Sweden (37)

Showing 20 results out of 10000

28 Mar 2023 | Company News

Keytruda plus chemotherapy reduce risk of endometrial cancer

Merck’s Phase III trial results demonstrate improved progression-free survival if chemotherapy treatment is complemented with Keytruda.

28 Mar 2023 | Comment

Further disappointment for anti-TIGITs: is there a future for this novel target?

An update from Merck & Co on its KeyVibe-002 trial featuring the TIGIT inhibitor vibostolimab, co-formulated with Keytruda (pembrolizumab), with…

28 Mar 2023 | News

Ionis and AstraZeneca report additional positive topline data from a Phase III ATTRv-PN trial

Eplontersen demonstrated statistically significant and clinically meaningful changes in patients with ATTRv-PN at 66 weeks of treatment.

28 Mar 2023 | Company News

Novartis Phase III Kisqali trial meets primary endpoint of iDFS

The findings showed that Kisqali plus ET reduced the risk of disease recurrence compared to ET alone.

28 Mar 2023 | Industry News

FDA to hold Advisory Committee meeting for BrainStorm’s NurOwn in ALS

In a surprising about-face, the FDA will convene an Advisory Committee to review BrainStorm Cell Therapeutics’s stem cell therapy NurOwn for ALS.

28 Mar 2023 | Company News

YS Biopharma reports positive data from Covid-19 vaccine trial

The trial assessed the safety, and efficacy of a booster dose of PIKA recombinant protein Covid-19 vaccine.

27 Mar 2023 | News

Novo Nordisk announces positive results from oral semaglutide trial

The PIONEER clinical programme evaluated the effects of the drug on HbA1c and body weight in people with type 2 diabetes.

27 Mar 2023 | Comment

Consumption of ultra-processed foods increases cancer risk

Noncommunicable diseases (NCDs), such as cardiovascular diseases, type 2 diabetes and some cancers, are collectively responsible for around 74% of…

27 Mar 2023 | Company News

US FDA releases draft guidance for cancer clinical trials

The draft guidance discusses ways to improve the data available for accelerated approval.

27 Mar 2023 | Company News

Neurelis announces dosing of first two cohorts in CCM therapy trial

The trial will assess the tolerability, pharmacokinetic parameters, and safety of NRL-1049 in healthy participants.

24 Mar 2023 | Comment

Racial disparities in US systemic lupus erythematosus severity

The increase in cases can be attributed to the projected increase in the population.

24 Mar 2023 | Comment

What would the world look like if we all went on a dopamine detox?

The idea behind the hypothetical detox is that we reset our brains’ reward pathways to become re-accustomed to more a natural level of dopamine release.

24 Mar 2023 | Company News

BridgeBio Pharma starts subject dosing in NSCLC therapy trial

The trial will assess the tolerability, preliminary efficacy, safety, and pharmacodynamics of BBP-398 along with Opdivo.

24 Mar 2023 | Company News

Enveric chooses Avance Clinical for anxiety disorders therapy trial

The Phase I clinical trial will measure the tolerability and safety of the company’s lead candidate, EB-373.

24 Mar 2023 | Company News

GRIN begins subject dosing in GRIN-related disorders therapy trial

The trial will assess the pharmacokinetics, safety, and effects on seizures, sleep, behavioural symptoms of radiprodil doses.

24 Mar 2023 | Company News

AbbVie reports data from systemic lupus erythematosus therapy trial

According to the findings, no new safety signals were identified with upadacitinib.

Projects

Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Olumiant® (baricitinib) is one of the first once-daily oral selective Janus kinase (JAK) inhibitors approved for the treatment of moderate-to-severe active…

Supplier Products

dabl Clinical Trial Solutions

Our Solution in 2 Minutes dabl® Clinical Trial Solutions Complete Solution for Management of Blood Pressure Data The dabl system offers…

23 Mar 2023 | Comment

AbbVie Parkinson’s drug ABBV-951 faces a few hurdles before FDA approval

ABBV-951’s continuous delivery system of levodopa holds great potential for controlling motor functions.

23 Mar 2023 | Company News

Syneos Health and KX partner for data-driven insights

The collaboration will deliver data-driven predictive analytics, AI and ML capabilities for customers.